Druck Icon

Eckert & Ziegler: Sales Grow by 32%, Profits by 40%

Berlin, 9 May 2006. Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700), a specialist for isotope applications in medicine and industry, posted record figures for the first quarter of 2006. Sales increased by 32% to 11.3 million EUR, and the quarterly surplus after taxes and distribution to other shareholders rose by 40% to 0.7 million EUR. The result per share for the quarter amounted to 0.21 EUR (last year: 0.15 EUR).

The Group's traditional segments (Nuclear Medicine & Industry segment, Therapy segment) were responsible for around two thirds of the growth in sales, or around 1.6 million EUR, while the new Radiopharmaceutical segment accounted for the rest (1.1 million EUR). The Therapy segment, which acquired no new companies last year, showed an organic growth in sales of 16%. The Nuclear Medicine & Industry segment, for which results from the American company Analytics Inc. and the Czech company SORAD s.r.o. are being consolidated for the first time in a first quarter, posted a 20% increase.

The increase in profit over the same quarter of last year derives primarily from higher sales in the Group's traditional segments and a higher than expected contribution from the Radiopharmaceutical segment. For the ongoing year, the Board of Directors anticipates sales of around 50 million EUR and a return to the profit level of the year before last (approx. 0.75 EUR per share).

Eckert & Ziegler is a globally active specialist for radiation applications in medicine, science and industry. Its main areas of activity are cancer therapy, nuclear medical diagnostics and measurement technology. Listed on the Frankfurt Prime Standard (ISIN DE0005659700), the Group is headquartered in Berlin-Buch and has approximately 280 employees. In addition to sites in Germany, it has subsidiaries in Los Angeles, Atlanta, Prague, Paris, Milan and Chennai (India).

The Board of Directors